Published in J Immunol on February 01, 1975
Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg (1977) 3.02
Isolation from human serum of an inactivator of bacterial lipopolysaccharide. Am J Pathol (1977) 1.58
Chemotactic factor inactivation by the myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest (1979) 1.39
Suppression of immune complex-induced inflammation by the chemotactic factor inactivator. J Clin Invest (1977) 1.33
A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest (1978) 1.28
Antileukotactic properties of tumor cells. J Clin Invest (1975) 1.19
Characteristics of the chemotactic response of neoplastic cells to a factor derived from the fifth component of complement. Am J Pathol (1978) 1.12
Characterization of the protease activity in the chemotactic factor inactivator. J Clin Invest (1976) 1.05
Serum chemotactic inhibitory activity: heat activation of chemotactic inhibition. Infect Immun (1976) 1.00
Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor. Ann Rheum Dis (1980) 0.97
Regulatory dysfunction in leukotaxis. Am J Pathol (1977) 0.85
A chemotactic inhibitor in synovial fluid. Immunology (1983) 0.84
Serum inhibitor of C5 fragment-mediated polymorphonuclear leukocyte chemotaxis associated with chronic hemodialysis. J Clin Invest (1979) 0.83
Neutrophil function in infection-prone children. Arch Dis Child (1980) 0.81
The regulation of tissue eosinophil chemotactic factor and inhibitor in allergic skin lesions of Freund's complete adjuvant-treated guinea-pigs. Immunology (1984) 0.81
Restoration by ketoprofen of defective neutrophil granulocyte migration induced in guinea-pigs by plasma from cancer patients. Br J Exp Pathol (1980) 0.78
Serum inhibitory effect on myeloperoxidase in human cancer. Br J Exp Pathol (1982) 0.75
In vitro and in vivo production of chemotactic inhibitors by tumor cells. Am J Pathol (1979) 0.75
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science (1989) 4.99
A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med (1967) 4.94
The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med (1968) 4.79
A neutrophil chemotactic factor from human C'5. J Immunol (1969) 4.46
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med (1967) 3.87
C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol (1970) 3.75
Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun (1988) 3.63
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
Acute immunologic pulmonary alveolitis. J Clin Invest (1974) 3.53
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem (1984) 3.32
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med (1967) 3.15
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Chemotoxis of mononuclear cells. J Exp Med (1968) 2.95
Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science (1993) 2.71
The chemosuppression of chemotaxis. J Exp Med (1966) 2.62
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest (1983) 2.52
Protective effects of C5a blockade in sepsis. Nat Med (1999) 2.50
Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest (1991) 2.50
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Role of oxygen metabolites in immune complex injury of lung. J Immunol (1981) 2.39
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol (1977) 2.26
Evidence for soluble immune complexes in the pathogenesis of the glomerulonephritis of quartan malaria. Lancet (1969) 2.22
C3 leukotactic factors produced by a tissue protease. J Exp Med (1969) 2.19
Human herpesvirus 6 in salivary glands. Lancet (1990) 2.15
Biochemical demonstration of the activatable esterase of the rabbit netrophil involved in the chemotactic response. J Immunol (1970) 2.12
In vivo damage of rat lungs by oxygen metabolites. J Clin Invest (1981) 2.10
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Pulmonary endothelial cell killing by human neutrophils. Possible involvement of hydroxyl radical. Lab Invest (1985) 2.01
Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol (1979) 1.96
Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol (1996) 1.95
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93
Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes. Am J Pathol (1978) 1.91
Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med (1967) 1.90
Leukotactic factors elaborated by virus-infected tissues. J Exp Med (1972) 1.89
Neutropenia induced by systemic infusion of chemotactic factors. J Immunol (1977) 1.89
Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology (1989) 1.88
Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med (1974) 1.88
Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest (1989) 1.86
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Impaired leucotactic responsiveness in a child with recurrent infections. Lancet (1969) 1.78
Selective neutrophil desensitization to chemotactic factors. J Cell Biol (1979) 1.77
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol (1993) 1.74
Leukotactic factors in health and disease. Am J Pathol (1971) 1.71
Impaired neutrophil chemotaxis in patients with juvenile and rapidly progressing periodontitis. J Periodontal Res (1979) 1.70
Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody. J Immunol (1993) 1.68
Neutrophil chemotactic factors and related clinical disorders. Arthritis Rheum (1970) 1.68
Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. J Biol Chem (2000) 1.66
Lung and dermal vascular injury produced by preformed immune complexes. Am Rev Respir Dis (1978) 1.64
Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis (1984) 1.64
C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest (1979) 1.63
Isolation from human serum of an inactivator of bacterial lipopolysaccharide. Am J Pathol (1977) 1.58
Influence of inhibitors of cellular function on chemotactic factor-induced neutrophil aggregation. J Immunol (1977) 1.57
Inhibition of in vivo and in vitro neutrophil responses to chemotactic factors by a competitive antagonist. J Immunol (1978) 1.55
Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol (1989) 1.55
Chemotaxis of human eosinophils. Am J Pathol (1969) 1.54
Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 1.53
Chemotaxis of rat lymphocytes. J Immunol (1977) 1.53
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol (1995) 1.53
Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (1995) 1.52
Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. J Immunol (1972) 1.51
Leukotactic dystunction in sarcoidosis. Ann Intern Med (1976) 1.50
Suppression by superoxide dismutase of immune-complex--induced pulmonary alveolitis and dermal inflammation. Am J Pathol (1981) 1.50
Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J (1989) 1.49
Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest (1993) 1.49
Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest (2000) 1.49
Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol (1997) 1.49
Chemoattractants of leukocytes, with special reference to lymphocytes. Fed Proc (1972) 1.48
Biochemical quantitation of the chemotactic factor inactivator activity in human serum. J Lab Clin Med (1979) 1.46
In vitro and in vivo stimulation of rat neutrophils and alveolar macrophages by immune complexes. Production of O-2 and H2O2. Am J Pathol (1983) 1.46
Congenital 21-hydroxylase deficiency as a new deletion mutation. Detection in a proband during subsequent prenatal diagnosis by HLA typing and DNA analysis. Hum Immunol (1992) 1.45
In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha. J Immunol (1999) 1.45
Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature (1993) 1.43
Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol (1997) 1.43
Neutrophil-dependent, oxygen-radical mediated lung injury associated with acute pancreatitis. Ann Surg (1989) 1.43
Oxygen radical dependent lung damage following thermal injury of rat skin. J Trauma (1983) 1.41
Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-1. J Immunol (1992) 1.41
Defective leukotaxis in patients with lepromatous leprosy. J Lab Clin Med (1976) 1.41
Chemotactic factor inactivators of human granulocytes. J Clin Invest (1977) 1.40
Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. Lab Invest (1984) 1.40
Those nasty radicals. West J Med (1986) 1.39
Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. J Neuroimmunol (1995) 1.39
Biologic activity of extracts of delayed hypersensitivity skin reaction sites. Cell Immunol (1973) 1.39
Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol (1993) 1.38
Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. J Immunol (1997) 1.37
Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature (1989) 1.37